Latest Morning Briefing Stories
Republican Convention, Day 4: Fireworks … and Shining a Light on Trump’s Claims
Donald Trump accepted his party’s nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
Trump Again Claims He’s Bringing Down Drug Prices, But Details of How Are Skimpy
During his Monday speech at the Republican National Convention, President Donald Trump pointed to his two of his recent executive orders as likely to lead to big reductions in prescription drug costs.
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Democratic Convention, Night 4: ‘Facts Over Fiction’ in Biden’s Speech
The impact of the novel coronavirus, and the current administration’s response to it, were central themes in Joe Biden’s presidential nomination acceptance speech.
KHN’s ‘What the Health?’: Kamala Harris on Health
The Democratic presidential ticket is complete, with Joe Biden’s selection of California Sen. Kamala Harris as his running mate. Health has not been a major issue for Harris, whose career priority has been the criminal justice system. But expect Republicans to pounce on her on-again, off-again support for “Medicare for All.” Meanwhile, with Congress still in a stalemate over another round of COVID-19 relief, President Donald Trump is trying to use his executive power to do what lawmakers have not — with mixed success. Kimberly Leonard of Business Insider, Joanne Kenen of Politico and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
What Seniors Can Expect as Their New Normal in a Post-Vaccine World
Experts say folks 60 and up must continue to limit exposure in the years to come — even after there is a vaccine for COVID-19.
Fauci Unfazed as Scientists Rely on Unproven Methods to Create COVID Vaccines
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
Don’t Fall for This Video: Hydroxychloroquine Is Not a COVID-19 Cure
This statement is taken from a video in which a group of doctors air unproven conspiracy theories about the coronavirus. Dr. Immanuel’s claims were among the most inaccurate. And, before it was removed from social media platforms, thee video was viewed millions of times. President Donald Trump retweeted it.
KHN’s ‘What The Health?’: Republicans in COVID Disarray
President Donald Trump’s sobering view of COVID-19 didn’t last long – this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk, who wrote the latest KHN-NPR “Bill of the Month” story about a surprise bill from a surprise surgical assistant.
Public Health Experts Fear a Hasty FDA Signoff on Vaccine
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
Must-Reads of the Week From Lauren Olsen
Newsletter editor Lauren Olsen wades through hundreds of health care policy stories each week, so you don’t have to.
Vacuna contra el coronavirus: ¿en qué punto está la investigación?
A principios de julio, había cerca de 160 ensayos de vacunas en todo el mundo, según la Organización Mundial de la Salud. Las tres vacunas más avanzadas se encuentran en la fase 3.
A Coronavirus Vaccine: Where Does It Stand?
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here’s an inventory of where things stand.
2021 Health Plans Granted Leeway To Limit Consumers’ Benefit From Drug Coupons
A rule finalized this spring by the Trump administration permits employers and insurers not to apply drug company copayment assistance toward enrollees’ deductibles and out-of-pocket maximums for any drug.
KHN’s ‘What the Health?’: SCOTUS, Trump Collide Over Transgender Rights
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN executive editor Damon Darlin wades through mounds of health care policy stories — so you don’t have to.
A Senator From Arizona Emerges As A Pharma Favorite
Sen. Kyrsten Sinema has received almost $100,000 from drug companies in the current election cycle, a KHN analysis shows, one of the largest cash hauls in Congress. And it’s only her first term.
Analysis: Get Ready For The Vaccine — They’re Never Simple
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Drugmakers Tout COVID-19 Vaccines To Refurbish Their Public Image
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Persiguiendo el esquivo sueño de una cura para COVID-19
Hay más de 1,250 estudios de COVID-19 en marcha. Las farmacéuticas están invirtiendo miles de millones en el desarrollo de medicamentos y vacunas eficaces para poner fin a la pandemia.
